Advances in biologic therapies for COPD: precision medicine approaches and implications for small-airway disease - PubMed

2 days ago

COPD is a progressive respiratory condition with persistent airflow limitation and chronic inflammation, primarily caused by smoking.
Current inhaled therapies improve symptoms but do not significantly alter disease progression, necessitating new treatments.
Biologic therapies show promise for COPD, especially for specific inflammatory endotypes, but require precision medicine approaches.
Small-airway disease plays a critical role in COPD, with advances in drug formulation and delivery technologies improving treatment.
Challenges in drug delivery include particle size affecting distal airway deposition, with innovations in nanotechnology offering solutions.
The review compares systemic versus inhaled therapeutic approaches, emphasizing the need for optimized airway-targeted delivery.
Long-term success of biologic therapies depends on integrating them with established inhaled treatments for meaningful disease modification.

Hasty Briefsbeta